Kaufman joins Serac at pivotal moment in the development of Seracam

Serac Imaging Systems has appointed James Kaufman as chief commercial officer, reporting to chief executive officer Mark Rosser. He brings almost 30 years of experience in the global healthcare and molecular imaging industry and will be responsible for leading the commercialisation of Seracam, a portable hybrid gamma-optical camera for medical imaging.

Kaufman joins from Jubilant Radiopharma where he served as vice president of global sales. His main areas of expertise include direct to physician marketing and sales, as well as business development, operations, supply chain and brand team management. He brings extensive knowledge in nuclear medicine and molecular imaging, with a specialisation in cardiology, neurology, oncology and general nuclear imaging segments. Prior to his role at Jubilant, Kaufman served as an executive global product leader for GE HealthCare in the life sciences division, among other leadership roles.

Kaufman said: “Serac Imaging Systems’ approach, designing a product for unmet diagnostic needs from the ground up using cutting-edge technology, has the potential to be a game-changer for patient care.”

Serac Imaging is developing Seracam to bring the benefits of high resolution molecular imaging to the patient’s bedside. It will enable users to see the uptake of targeted tracers, labelled with minute amounts of radioactivity, in patients in a wide range of settings.

Rosser added: “We are excited to welcome Jim to the team at such a pivotal point, with clinical testing of Seracam now well underway, and feedback from patients and physicians imminent. With his wealth of experience in nuclear medicine and medical imaging, combined with his business development prowess, Jim will play a significant role in driving Seracam forward through its next stages of development.”

Picture: James Kaufman

Published on page 27 of the August 2023 issue of RAD Magazine.


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more